BioXcel Therapeutics and Nektar Therapeutics Present Preclinical Pancreatic Cancer Data for BXCL701, NKTR-214 and Anti-PD1 Combination Therapy at ASCO 2018 Annual Meeting

Jun 4, 2018

BioXcel Therapeutics to Present at 2018 UBS Global Healthcare Conference

May 18, 2018

BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting

May 17, 2018

BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

May 14, 2018

BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting

Apr 26, 2018

BioXcel Therapeutics to Ring the NASDAQ Stock Market Opening Bell on April 20, 2018

Apr 19, 2018

BioXcel Therapeutics Announces Closing of Initial Public Offering

Mar 12, 2018

BioXcel Therapeutics Announces Pricing of Initial Public Offering

Mar 8, 2018

BioXcel Therapeutics Files Registration Statement for Proposed Initial Public Offering

Feb 13, 2018

New Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate BXCL701 in Combination with NKTR-214 in Multiple Oncology Indications

Nov 13, 2017